BioAtla, Inc. (NASDAQ:BCAB) Short Interest Update

BioAtla, Inc. (NASDAQ:BCAB) was the recipient of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 4,400,000 shares, a growth of 11.4% from the December 31st total of 3,950,000 shares. Based on an average daily volume of 1,120,000 shares, the short-interest ratio is currently 3.9 days.

BioAtla Trading Down 4.9 %

BCAB stock traded down $0.02 during midday trading on Monday, reaching $0.45. 1,086,268 shares of the company’s stock traded hands, compared to its average volume of 1,042,670. BioAtla has a 52-week low of $0.43 and a 52-week high of $4.02. The stock’s 50-day moving average is $0.92 and its 200 day moving average is $1.50. The stock has a market cap of $21.61 million, a P/E ratio of -0.26 and a beta of 1.14.

BioAtla (NASDAQ:BCAB) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.12. The company had revenue of $11.00 million for the quarter. During the same period in the previous year, the company earned ($0.70) earnings per share. As a group, research analysts expect that BioAtla will post -1.46 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright cut BioAtla from a “buy” rating to a “neutral” rating in a research report on Wednesday, November 13th.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. American Century Companies Inc. boosted its stake in shares of BioAtla by 36.1% in the second quarter. American Century Companies Inc. now owns 43,391 shares of the company’s stock worth $59,000 after acquiring an additional 11,503 shares during the period. Dimensional Fund Advisors LP increased its holdings in BioAtla by 28.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 333,858 shares of the company’s stock valued at $458,000 after acquiring an additional 73,598 shares during the last quarter. Bank of Montreal Can boosted its stake in BioAtla by 55.1% during the second quarter. Bank of Montreal Can now owns 404,198 shares of the company’s stock valued at $554,000 after buying an additional 143,521 shares during the last quarter. AQR Capital Management LLC purchased a new position in shares of BioAtla in the second quarter valued at $872,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in BioAtla in the second quarter worth about $99,000. Institutional investors own 77.23% of the company’s stock.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.